Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Baricitinib (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-114
Last updated

Report documents

  1. Extract of dossier assessment

    Baricitinib (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF-Dokument, 291 kB, EN, PDF
    DOI-Link
    https://doi.org/10.60584/A23-114_en
    Download file : Extract of dossier assessment (PDF-Dokument, 291 kB, EN, PDF)

  2. Dossier assessment

    Baricitinib (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    LNK-Dokument, 3 kB, PDF
    DOI-Link
    https://doi.org/10.60584/A23-114
    Download file : Dossier assessment (LNK-Dokument, 3 kB, PDF)

Dossier assessment

Indication:

Children and adolescents with active enthesitis-related psoriatic arthritis who have had an inadequate response or intolerance to one or more conventional synthetic or biologic disease-modifying antirheumatic drugs (DMARDs)

Result of dossier assessment:
  • Children 2 to 5 years of age: added benefit not proven
  • Children and adolescents 6 years of age and older: added benefit not proven

Project details

Project no.
A23-114
Commission
Commission awarded on 14.12.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Children's and adolescents' health
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI
https://doi.org/10.60584/A23-114_en

Connected Projects

  1. Dossier assessment

    Baricitinib (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-113
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Baricitinib (atopic dermatitis, 2 to 17 years) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-109
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Baricitinib (juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-108
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-14
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Baricitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-95
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page